Relatlimab plus nivolumab demonstrated clinical activity and a manageable safety profile in a phase I/II trial in heavily pretreated patients with melanoma and progression on prior anti-PD- 1/anti-PD-L1 therapy [43]. Here, CD274 is linked to melanoma.